network member

University of Michigan Rogel Cancer Center

1500 East Medical Center Drive, Ann Arbor, MI 48109 - USA
University of Michigan Rogel Cancer Center

About Network Member

The University of Michigan Rogel Cancer Center was founded in 1986; it received its NCI designation as a cancer center in 1988 and its comprehensive designation in 1991. The Center is also a founding member of the National Comprehensive Cancer Network. The Rogel Cancer Center brings together in one place more than 400 scientists and clinicians in multidisciplinary teams devoted to cancer research and patient care. The Rogel Cancer Center has a distinguished history of scientific excellence, collaboration and impact in basic science, clinical research and cancer control research. Through our focus on team science and research excellence, we are advancing knowledge in prevention, early diagnosis, optimal treatment and survivorship care for those at risk of or affected by cancer. Our mission is to reduce cancer burden and improve cancer outcomes through research, innovation, collaboration, education, outreach and engagement. Clinical research teams include: biomedical prevention and genetics; bone marrow transplant, breast oncology; childhood cancer; connective tissue oncology; cutaneous oncology; experimental therapeutics; gastrointestinal oncology; genitourinary oncology; gynecologic oncology; head and neck oncology and endocrine malignancies; hematologic malignancies; neurologic oncology; and thoracic oncology. We also have a strong focus on outcomes and disparities research. With members from 53 departments across 9 top-ranked University of Michigan schools, we are harnessing the power of one of the largest, most robust and highly esteemed research universities in the world to create new knowledge about cancer. As part of Michigan Medicine, the Rogel Cancer Cancer offers multidisciplinary clinics in 24 different cancer types. In each of these clinics, specialized physicians, including dedicated pathologists and radiologists, collaborate to provide comprehensive care for each patient. We take the same approach when supporting patients during treatment. Cancer specialists in psychology, social work, art therapy, nutrition, finance and countless other areas are an integral part of patients’ care team. Michigan’s teams of physicians and nurses work with colleagues in local communities to provide ongoing care for cancer patients and their families. Risk evaluations, genetic counseling, and fertility counseling are also provided. Website: University of Michigan Rogel Cancer Center
Mathew Innes, BSE, MBA
Currently Enrolling

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
New York University Cancer Institute
Orlando Health Cancer Institute
Parkview Research Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
Tufts Medical Center
University of Alabama at Birmingham Comprehensive Cancer Center
University of Arizona Cancer Center
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Michigan Health-West
University of Michigan Rogel Cancer Center
University of Virginia Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

HCRN-BRE21-516

BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib
Cancer areas:Breast
Dana-Farber Cancer Institute
Duke Cancer Institute
MD Anderson Cancer Center
Novant Health Oncology Specialists
Providence Cancer Institute
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
The Ohio State University
UC San Francisco
University of Michigan Rogel Cancer Center
Enrollment Closed

HCRN-GU19-385

Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC)
Cancer areas:Prostate
City of Hope
Froedtert & the Medical College of Wisconsin
Knight Cancer Institute at Oregon Health & Science University
University of Michigan Rogel Cancer Center
Winship Cancer Institute of Emory University
Currently Enrolling

HCRN-LYM21-544

Phase 2, open label, multicenter study of pacritinib in relapsed/refractory T-cell lymphoproliferative neoplasms
Cancer areas:Lymphoma
City of Hope
The Ohio State University
University of Michigan Rogel Cancer Center
Currently Enrolling

HCRN-LYM21-546

A phase II study of pembrolizumab and mogamulizumab in advanced-stage, relapsed/refractory cutaneous T-cell lymphomas
Cancer areas:Lymphoma
University of Michigan Rogel Cancer Center
Enrollment Closed

BTCRC-HN17-111

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
Cancer areas:Head and Neck
Masonic Cancer Center, University of Minnesota
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
University of Michigan Rogel Cancer Center
University of Wisconsin Carbone Cancer Center